alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Company profile
Ticker
ALNY
Exchange
Website
CEO
John Maraganore
Employees
Location
Fiscal year end
Industry (SIC)
Former names
ALNYLAM PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Alnylam U.S., Inc. • Alnylam Securities Corporation • Sirna Therapeutics, Inc. • Alnylam Austria GmbH • Alnylam Brasil Farmaceutica Ltda. • Alnylam (Bermuda) Ltd. • Alnylam Canada ULC • Alnylam France SAS • Alnylam Europe AG • Alnylam Germany GmbH ...
IRS number
770602661
ALNY stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
20 May 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2 May 24
ARS
2023 FY
Annual report to shareholders
1 Apr 24
DEFA14A
Additional proxy soliciting materials
1 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Results of Operations and Financial Condition
15 Feb 24
8-K
Departure of Directors or Certain Officers
19 Jan 24
Transcripts
ALNY
Earnings call transcript
2024 Q1
2 May 24
ALNY
Earnings call transcript
2023 Q4
15 Feb 24
ALNY
Earnings call transcript
2023 Q3
2 Nov 23
ALNY
Earnings call transcript
2023 Q2
3 Aug 23
ALNY
Earnings call transcript
2023 Q2
3 Aug 23
ALNY
Earnings call transcript
2023 Q1
4 May 23
ALNY
Earnings call transcript
2022 Q4
23 Feb 23
ALNY
Earnings call transcript
2022 Q3
27 Oct 22
ALNY
Earnings call transcript
2022 Q2
28 Jul 22
ALNY
Earnings call transcript
2022 Q1
28 Apr 22
Latest ownership filings
4
AMY W SCHULMAN
31 May 24
144
Notice of proposed sale of securities
29 May 24
4
DAVID E I PYOTT
20 May 24
4
PETER N KELLOGG
20 May 24
4
Carolyn R Bertozzi
20 May 24
4
Charles Elliott Sigal
20 May 24
4
OLIVIER BRANDICOURT
20 May 24
4
MARGARET A HAMBURG
20 May 24
4
Colleen F Reitan
20 May 24
4
MICHAEL W BONNEY
20 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 684.72 mm | 684.72 mm | 684.72 mm | 684.72 mm | 684.72 mm | 684.72 mm |
Cash burn (monthly) | 43.39 mm | (no burn) | 21.20 mm | 21.80 mm | 27.17 mm | (no burn) |
Cash used (since last report) | 91.32 mm | n/a | 44.61 mm | 45.88 mm | 57.19 mm | n/a |
Cash remaining | 593.40 mm | n/a | 640.11 mm | 638.84 mm | 627.53 mm | n/a |
Runway (months of cash) | 13.7 | n/a | 30.2 | 29.3 | 23.1 | n/a |
Institutional ownership, Q1 2024
88.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 477 |
Opened positions | 165 |
Closed positions | 66 |
Increased positions | 140 |
Reduced positions | 108 |
13F shares | Current |
---|---|
Total value | 15.39 tn |
Total shares | 111.32 mm |
Total puts | 1.65 mm |
Total calls | 2.75 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Capital World Investors | 12.79 mm | $1.91 tn |
Vanguard | 11.99 mm | $1.79 tn |
FMR | 9.97 mm | $1.49 tn |
BLK Blackrock | 9.03 mm | $1.35 tn |
Wellington Management | 7.21 mm | $1.08 tn |
Baillie Gifford & Co | 6.62 mm | $989.89 bn |
Dodge & Cox | 3.81 mm | $569.63 bn |
T. Rowe Price | 3.69 mm | $550.84 mm |
Capital International Investors | 3.65 mm | $545.67 bn |
STT State Street | 3.19 mm | $476.95 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 May 24 | Schulman Amy W | Common Stock | Sell | Dispose S | No | Yes | 149.76 | 63 | 9.43 k | 8,436 |
29 May 24 | Schulman Amy W | Common Stock | Sell | Dispose S | No | Yes | 148.93 | 11,516 | 1.72 mm | 8,499 |
29 May 24 | Schulman Amy W | Common Stock | Sell | Dispose S | No | Yes | 148.21 | 10,121 | 1.50 mm | 20,015 |
29 May 24 | Schulman Amy W | Common Stock | Option exercise | Acquire M | No | Yes | 66.83 | 30,000 | 2.00 mm | 30,136 |
29 May 24 | Schulman Amy W | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 66.83 | 30,000 | 2.00 mm | 0 |
16 May 24 | Sharp Phillip A | Stock Option Common Stock | Grant | Acquire A | No | No | 151.22 | 5,228 | 790.58 k | 5,228 |
16 May 24 | Ausiello Dennis A | Stock Option Common Stock | Grant | Acquire A | No | No | 151.22 | 5,228 | 790.58 k | 5,228 |
16 May 24 | Schulman Amy W | Stock Option Common Stock | Grant | Acquire A | No | No | 151.22 | 5,228 | 790.58 k | 5,228 |
16 May 24 | Hamburg Margaret A | Stock Option Common Stock | Grant | Acquire A | No | No | 151.22 | 5,228 | 790.58 k | 5,228 |
News
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
17 May 24
10 Health Care Stocks With Whale Alerts In Today's Session
9 May 24
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $400
7 May 24
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $225 Price Target
3 May 24
Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price Target
2 May 24
Press releases
Alnylam Issues 2023 Corporate Responsibility Report
7 May 24
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2 May 24
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
30 Apr 24
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
30 Apr 24
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
7 Apr 24